Audited Standalone Financial Results for the half year and year ended 31.03.2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Astonea Labs reported revenue from operations of Rs 147.58 crore for FY 2025-26, a strong 51.33% growth from Rs 97.52 crore in the previous year. However, profitability declined as EBITDA fell 8.73% to Rs 13.80 crore with margins compressing to 9.35% from 15.50%, and PAT dropped 15.51% to Rs 4.52 crore. The company cited deliberate investments in distribution expansion and brand building for the margin compression. A fire incident occurred on 27th April 2026 at the factory causing Rs 9.39 crore losses with no insurance claim filed yet. The company terminated agreements with Astonea One Private Limited effective July 2026 and approved Rs 34 crore in related party transactions for FY 2026-27. The company made a Rs 6.25 crore strategic investment in Damaira Pharmaceuticals (25.74% stake) using IPO proceeds.
Strong topline growth is positive but margin compression and PAT decline may concern short-term investors. The fire incident and unfiled insurance claim add operational risk. The debt-to-equity ratio improved significantly to 0.36x from 1.32x, providing financial flexibility. Management guides for FY 2026-27 revenue growth of 45-55% and EBITDA margin recovery to 13-15%.